TriNetX Unveils Self-Service Precision Medicine Analytics for the Research Community
Cambridge, MA, September 25, 2018 - TriNetX, the global health research network that optimizes clinical research and enables discoveries through the creation of real-world evidence, showcased today a series of new analytical tools that enable more people to conduct health research on their own. These new capabilities build upon TriNetX Research™, a product line launched earlier this year. The company unveiled its latest R&D efforts at its annual users summit being held this week in Boston. “We are continually looking for ways to help our clients leverage real-world data from millions of patients that we are collecting and updating,” said Steve Kundrot, Chief Technology Officer at TriNetX. “These analytical tools are part of our vision to build a health research network that enables more people to conduct meaningful research on a unique data set, at an unprecedented scale and among a community that has never been enabled to collaborate in this way before.” The new capabilities that TriNetX demonstrated included Patient Journey Analytics, Bring Your Own Model, and Cohort Monitoring.
- Patient Journey Analytics help users understand what happens to a patient in the real world before and after they are diagnosed with a disease. Users will be able to track the treatments patients are receiving, discover when and why they switch to new treatments, understand what comorbidities they develop, and compare patients on different care journeys.
- Bring Your Own Model allows users to apply their own statistical model to the TriNetX network to derive predictions and characteristics for their specific needs. For example, a model might discover patients with rare and undiagnosed conditions, or score patients on the risk of a health-related event occurring. Bring Your Own Model moves the analytical models to the data, rather than centralizing data for analysis, so that users can run models across the secure TriNetX network without having direct access to patient clinical data. This ensures compliance with all privacy standards and regulations including HIPAA and GDPR.
- Cohort Monitoring allows researchers to monitor cohorts prospectively by creating cohorts of patients and tracking their health going forward in an aggregated, de-identified manner. With these new observational capabilities, TriNetX can help biopharma execute non-interventional trials in a more seamless and efficient manner.
“We developed these tools to put health research into the hands of more people,” said Alex Eastman, Vice President, Product Management at TriNetX. “These new capabilities break down silos and enable users to access our unmatched, longitudinal data set and get answers in minutes - and they don’t have to be data scientists to do it.” TriNetX’s cloud-based platform, TNX™, provides on-demand access to longitudinal clinical data and a set of highly intuitive analytics capabilities, enabling researchers to explore and compare cohorts, including reviewing cohort characteristics prior to an event and comparing outcomes of interest after the event. TriNetX has partnered with over 80 healthcare organizations, spanning 16 countries, to deploy a continually updated global health research network representing over 135 million patients. TriNetX implements and configures hardware and software into its healthcare organization members’ IT infrastructure that often builds on existing data resources. Researchers then have access to the institution’s de-identified patient data through a user-friendly interface and a growing number of visualization and analysis capabilities. ####
About TriNetX
TriNetX is the global health research network that optimizes clinical research and enables discoveries through the creation of real-world evidence. TriNetX combines real time access to longitudinal clinical data with state-of-the-art analytics to answer complex research questions at the speed of thought. For more information, visit TriNetX at
http://www.trinetx.com
or follow
@TriNetX
on Twitter.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
